Merck Stock News

The World Health Organization on Wednesday recommended an anti-Covid pill be taken by sufferers who have mild symptoms but are at high risk of hospitalisation, such as older people or the…

A World Health Organization (WHO) panel on Wednesday backed the use of Merck & Co Inc''s COVID-19 antiviral pill for high-risk patients.

… Read more Merck Enters Today Down -0.31% The post Merck Enters Today Down -0.31% appeared first on CFDTrading .

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.'s (NASDAQ: AG

Investors don't have to dive into confusing business models or new technologies to generate good, reliable dividend income.

MSD in the Philippines, a trade name of Merck & Co. Inc, Kenilworth, NJ, USA, has announced the…

… Read more Merck Came Into Today Down -0.18% The post Merck Came Into Today Down -0.18% appeared first on CFDTrading .

Las Vegas, USA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Dengue Fever Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight Dengue Fever Pipeline constitutes 20+ key companies continuously working towards developing 20+ Dengue Fever treatment therapies, analyzes DelveInsight DelveInsight''s ‘ Dengue Fever Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Dengue Fever pipeline domain. Some of the essential takeaways from the Dengue Fever Pipeline report: DelveInsight''s Dengue Fever Pipeline analysis depicts a robust space with 20+ active players proactively working to develop 20+ pipeline treatment therapies. Some of the key Dengue companies working to develop potential drug candidates to improve the Dengue Fever treatment scenario include Kino Pharma, Emergex Vaccines, Abivax, Plex Pharmaceuticals, Takeda, Merck Sharp & Dohme, Immunoforge, Chugai Pharmaceutical Co., Ltd, Codagenix, Biotron Ltd, GlaxoSmithKline, Ennaid therapeutics, AbViro LLC, Medigen Vaccine Biologics Corp., Atea Pharmaceuticals, Visterra, Janssen Research & Development, Globavir Biosciences, Serum Institute of India, BioNet Asia, and many others.

Merck & Company Inc (new''s (NYSE: MRK ) short percent of float has fallen 13.98% since its last report. The company recently reported that it has 20.09 million shares sold short , which is 0.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.4 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of … Full story available on Benzinga.com

Celyad Oncology SA (NASDAQ: CYAD ) has decided to voluntarily pause the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial, a part of a collaboration with Merck & Co Inc (NYSE: MRK ). The trial is evaluating the company''s CYAD-101 administered concurrently with FOLFOX chemotherapy, … Full story available on Benzinga.com

MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ: CYAD ) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it has taken the decision to voluntarily pause the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial (NCT04991948). The CYAD-101-002 trial is part of a collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, through a subsidiary. The trial is evaluating the Company''s TCR Inhibitory Molecule (TIM)-based allogeneic NKG2D CAR T cell investigational therapy CYAD-101 administered concurrently with FOLFOX chemotherapy, followed by MSD''s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with refractory metastatic colorectal cancer. The Company has received reports of two fatalities that presented with similar pulmonary findings. With a clear focus on patient safety and an overriding sense of caution, the Company has decided to voluntarily pause dosing and enrollment of patients in the CYAD-101-002 trial in order to investigate these events.

TOKYO—Drugmaker Shionogi & Co. Ltd. has applied for approval to make and sell its oral COVID-19 treatment in Japan, the firm said on Friday. Known as S-217622, the drug would become the country’s third antiviral pill approved for coronavirus patients, following those developed by Pfizer Inc. and Merck & Co.. In a statement, Shionogi said […]

The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Merck & Co Inc''s (NYSE: MRK ) Keytruda/Lenvima combo therapy for radically unresectable or metastatic renal cell carcinoma (RCC). Lenvima is an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai Co Ltd (OTC: Full story available on Benzinga.com

Merck (MRK) and Eisai''s (ESALF) (ESALY) drug combination of Keytruda and Lenvima was approved in Japan for radically unresectable or metastatic renal cell carcinoma ((RCC)), a type…

KENILWORTH, N.J. & TOKYO--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma